Evaluation of 3-month follow-up of patients with postacute COVID-19 syndrome.
postacute COVID-19
pulmonary function test
radiological sign
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
23
12
2021
received:
23
10
2021
accepted:
05
01
2022
pubmed:
11
1
2022
medline:
24
3
2022
entrez:
10
1
2022
Statut:
ppublish
Résumé
In addition to the highly variable clinical presentation of acute COVID-19 infection, it can also cause various postacute signs and symptoms. This study aimed to evaluate patients with postacute COVID-19 over 12 weeks of follow-up. The study included 151 patients who were diagnosed with COVID-19 by real-time polymerase chain reaction of a nasopharyngeal swab 1 month earlier, had radiologic findings consistent with COVID-19 pneumonia, and presented to the post-COVID-19 outpatient clinic between May and August 2021. The patients were divided into three groups based on COVID-19 severity: nonsevere pneumonia (Group 1), severe pneumonia (Group 2), and severe pneumonia requiring intensive care (Group 3). Evaluation of laboratory parameters at 4 and 12 weeks showed that Group 3 had a higher lactose dehydrogenase (LDH) level and a lower mean platelet volume than the other groups at both time points (p = 0.001 for all). Group 3 also had lower percent predicted forced vital capacity (FVC%), percent predicted forced expiration volume in 1 s (FEV1%), and percent predicted diffusion capacity of the lungs for carbon monoxide divided by alveolar volume (DLCO/VA%) compared to Groups 1 and 2 at Week 4 (p = 0.001, 0.004, 0.001, respectively) and compared to Group 1 at 12 weeks (p = 0.002, 0.03, 0.001, respectively). Patients with persistent dyspnea at 12 weeks had significantly lower FEV1%, FVC%, DLCO/VA%, and saturation levels in room air and significantly higher LDH, pro-BNP, D-dimer, and heart rate compared to those without dyspnea (p = 0.001 for all). Although the lungs are most commonly affected after COVID-19 infection, vascular and endothelial damage also causes multisystem involvement. Our study indicates that laboratory values, radiological signs, and pulmonary functional capacity improved in most patients after 12 weeks of follow-up.
Identifiants
pubmed: 35001367
doi: 10.1002/jmv.27579
pmc: PMC9015610
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2026-2034Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.
Qiao J. What are the risks of COVID-19 infection in pregnant women? Lancet. 2020;395(10226):760-762.
Kerget B, Kerget F, Kocak AO, et al. Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung. 2020;198(5):777-784.
Kerget B, Aksakal A, Kerget F. Evaluation of the relationship between laboratory parameters and pulmonary function tests in COVID-19 patients. Int J Clin Pract. 2021;75:e14237.
Montani D, Savale L, Beurnier A, et al. Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. Eur Respir J. 2021;58:(1):2101090.
Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nature Med. 2021;27(4):601-615.
Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55(6):2001217.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88.
Behan PO, Behan W. Postviral fatigue syndrome. Crit Rev Neurobiol. 1988;4(2):157-178.
Lidbury BA. Ross River Virus immune evasion strategies and the relevance to post-viral fatigue, and myalgic encephalomyelitis onset. Front Med. 2021;8:298.
Seet RC, Quek AM, Lim EC. Post-infectious fatigue syndrome in dengue infection. J Clin Virol. 2007;38(1):1-6.
Garcia MN, Hause AM, Walker CM, Orange JS, Hasbun R, Murray KO. Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines. Viral Immunol. 2014;27(7):327-333.
Hotchin N, Read R, Smith D, Crawford D. Active Epstein-Barr virus infection in post-viral fatigue syndrome. J Infect. 1989;18(2):143-150.
Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Paper presented at: open Forum Infectious Diseases; 2020.
Ahmed H, Patel K, Greenwood DC, et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med. 2020;52(5):00063.
Park WB, Jun KI, Kim G, et al. Correlation between pneumonia severity and pulmonary complications in Middle East respiratory syndrome. J Korean Med Sci. 2018;33(24):169.
Karimi-Galougahi M, Naeini AS, Raad N, Mikaniki N, Ghorbani J. Vertigo and hearing loss during the COVID-19 pandemic-is there an association? Acta Otorhinolaryngol Ital. 2020;40(6):463-465.
Lamontagne SJ, Winters MF, Pizzagalli DA, Olmstead MC. Post-acute sequelae of COVID-19: evidence of mood & cognitive impairment. Brain Behav Immun Health. 2021;17:100347.
Menter T, Haslbauer JD, Nienhold R, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology. 2020;77(2):198-209.
Salehi S, Reddy S, Gholamrezanezhad A. Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect. J Thorac Imaging. 2020;35(4):W87-W89.